The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|January 2, 2025
Dermatology Conferences and Meetings Calendar: January 2025
Author(s)Emma Andrus, Associate Editor
Listen
0:00 / 0:00
Key Takeaways
- Dermatology Times compiled a list of January 2025 dermatological meetings based on reader feedback.
- Readers are encouraged to share their conference interests or plans for 2025 by emailing the editorial team.
Dermatology Times has compiled a list of dermatological meetings taking place during the month of January.
Advertisement
Dermatology Times has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025.
Using these responses, we have compiled a list of dermatological meetings taking place in January.
Interested in sharing what conferences you are interested in or planning to attend this year? Email our team at
January
January 12, 2025: Advancing Innovation in Dermatology Summit 2025
San Francisco, California
January 20-24, 2025: Maui Derm Hawaii
Maui, Hawaii
January 30-February 1, 2025: IMCAS World Congress
Paris, France
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
FDA Revises TB Evaluation Guidance for SKYRIZI
5